Join Growin Stock Community!

樂斯科6662.TW Overview

TW StockBiotech. & Medical
(No presentation for 6662)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

樂斯科(6662)Overall Performance

樂斯科(6662)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

樂斯科(6662) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

樂斯科(6662)Key Information

樂斯科(6662)Profile

BioLASCO Taiwan Co., Ltd. provides bio-materials and surgical services in Taiwan and internationally. It breeds and produces SPF laboratory rats and mice, including outbreed stocks, inbreed strains, and immune deficient models, as well as offers special animal model services. The company also provides endotoxin detection, animal heath diagnostic, and serological kits, as well as biological indicators. In addition, it offers IVC systems and ventilated houses equipment; professional and automated animal watering systems; transponders; chlorine dioxide gas generators; mouse and rat tail cuff blood pressure systems, analgesia equipment, and animal behavioral equipment; metabolism and behavior systems, and trackers; XPERT cabinet X-ray systems; automatic cleaning equipment; workstations; isolation chambers; and foggers. BioLASCO Taiwan Co., Ltd. was founded in 1990 and is based in Taipei, Taiwan.

樂斯科(6662)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.75
PE Ratio (TTM)
16.92
Forward PE
-
PS Ratio (TTM)
2.73
PB Ratio
1.71
Price-to-FCF
14.47
METRIC
VALUE
vs. INDUSTRY
Gross Margin
41.67%
Net Margin
16.14%
Revenue Growth (YoY)
7.36%
Profit Growth (YoY)
12.60%
3-Year Revenue Growth
3.91%
3-Year Profit Growth
-1.25%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.75
PE Ratio (TTM)
16.92
Forward PE
-
PS Ratio (TTM)
2.73
PB Ratio
1.71
Price-to-FCF
14.47
Gross Margin
41.67%
Net Margin
16.14%
Revenue Growth (YoY)
7.36%
Profit Growth (YoY)
12.60%
3-Year Revenue Growth
3.91%
3-Year Profit Growth
-1.25%
default symbol

6662

樂斯科

29.55D

-0.51%

(-0.01)

  • When is 6662's latest earnings report released?

    The most recent financial report for 樂斯科 (6662) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6662's short-term business performance and financial health. For the latest updates on 6662's earnings releases, visit this page regularly.

  • Where does 6662 fall in the P/E River chart?

    According to historical valuation range analysis, 樂斯科 (6662)'s current price-to-earnings (P/E) ratio is 15.37, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 6662?

    According to the latest financial report, 樂斯科 (6662) reported an Operating Profit of 11.89M with an Operating Margin of 18.8% this period, representing a decline of 10.79% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6662's revenue growth?

    In the latest financial report, 樂斯科 (6662) announced revenue of 63.22M, with a Year-Over-Year growth rate of -8.04%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6662 have?

    At the end of the period, 樂斯科 (6662) held Total Cash and Cash Equivalents of 72.26M, accounting for 0.12 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6662 go with three margins increasing?

    In the latest report, 樂斯科 (6662) achieved the “three margins increasing” benchmark, with a gross margin of 41.65%%, operating margin of 18.8%%, and net margin of 12.83%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6662's profit trajectory and future growth potential.

  • Is 6662's EPS continuing to grow?

    According to the past four quarterly reports, 樂斯科 (6662)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6662?

    樂斯科 (6662)'s Free Cash Flow (FCF) for the period is 1.35M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 70.73% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.